Shots:

• FDC has launched two variants of Favipiravir under the brand names PiFLU and Favenza to treat mild to moderate COVID-19 in India. The products will be available across the country
• Both the variant will be available at $0.74 (Rs. 55) /tablet. The DCGI had earlier approved the use of Favipiravir as an off-patent- oral antiviral drug that has shown clinical recovery in COVID-19 patients with mild to moderate symptoms
• Additionally- FDC has increased the production of Enerzal and Electral- as according to ASPEN guidelines- 03 liters of fluid intake in a day (60-20ml in every 30 min) helps in speedy recovery of people who are home quarantined

­ Ref: FDC | Image:  Business Insider